Extract
The term chronic pulmonary aspergillosis (CPA) is used to describe a wide range of severe chronic fungal infections mainly occurring in non-immunocompromised patients with pre-existing lung disease [1]. CPA is a long-term infection of the lung caused by moulds of the genus Aspergillus. In Europe, the majority of cases are caused by A. fumigatus. About three million people are diagnosed with CPA globally, mostly complicating tuberculosis, allergic bronchopulmonary aspergillosis (ABPA) or sarcoidosis [2].
Abstract
Chronic pulmonary aspergillosis is a destructive fungal disease complicating many respiratory disorders. Evidence is scarce for clinical management decisions. CPAnet aims to improve patient care by collecting data in an international registry. https://bit.ly/3utUFH1
Acknowledgements
This article was written on behalf of all CPAnet members. We thank the ERS for being selected as an ERS Clinical Research Collaboration.
Footnotes
Author contributions: All authors contributed equally.
Conflict of interest: All authors have nothing to disclose.
- Received November 7, 2021.
- Accepted February 1, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
